Renaissance Technologies LLC Has $757,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Renaissance Technologies LLC lifted its position in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 6.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 582,689 shares of the company’s stock after buying an additional 35,900 shares during the quarter. Renaissance Technologies LLC owned about 0.78% of Clearside Biomedical worth $757,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Clearside Biomedical in the first quarter valued at $49,000. International Assets Investment Management LLC bought a new position in Clearside Biomedical during the first quarter worth about $57,000. Assenagon Asset Management S.A. acquired a new position in Clearside Biomedical during the second quarter worth approximately $368,000. Finally, Vanguard Group Inc. raised its stake in Clearside Biomedical by 14.5% in the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after buying an additional 314,480 shares during the period. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Clearside Biomedical Price Performance

CLSD stock opened at $1.48 on Wednesday. The business’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $1.23. The stock has a market capitalization of $110.60 million, a price-to-earnings ratio of -2.69 and a beta of 2.35. Clearside Biomedical, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the company posted ($0.15) earnings per share. Research analysts expect that Clearside Biomedical, Inc. will post -0.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 13th. Oppenheimer assumed coverage on shares of Clearside Biomedical in a research report on Tuesday, June 25th. They set an “outperform” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, August 27th. Finally, Chardan Capital assumed coverage on shares of Clearside Biomedical in a report on Wednesday, August 21st. They set a “buy” rating and a $6.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.83.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.